MAIA Biotechnology raises ~$2.92M in private placement of common stock and warrants

MAIA Biotechnology, Inc.

Sold 2,043,587 shares and warrants to accredited investors at $1.17/share for ~$2.4M gross.
Directors purchased 452,731 shares and warrants at same price, raising ~$530,000.
Warrants exercisable at $1.30 per share, beginning 6 months after issuance, 5-year term.
Net proceeds to fund first third of pivotal THIO-101 trial Part C in NSCLC.
Closing expected March 14, 2024; securities are restricted, no registration rights.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

MAIA Biotechnology, Inc. entered into Securities Purchase Agreement with certain accredited investors valued at approximately $2.4 million (effective 2024-03-11).

Action: entry
Agreement: equity purchase
Counterparty: certain accredited investors
Value: approximately $2.4 million
Effective: 2024-03-11

Exact text from the filing

On March 11, 2024, MAIA Biotechnology, Inc. (the " Company ") entered into a Securities Purchase Agreement (the " Purchase Agreement ") with certain accredited investors (the " Investors ") for the issuance and sale in a private placement (the " Private Placement ") of (i) 2,043,587 shares (the "Investor Shares") of the Company’s common stock, par value $0.0001 per share (" Common Stock "), and (ii) warrants (the " Investor Warrants ") to purchase up to 2,043,587 shares of the Company’s Common Stock, at a price per share of $1.17 for an aggregate purchase price of approximately $2.4 million.

View on SEC.gov

565 material agreements filed in the last 30 days. Browse all material agreements →

MAIA Biotechnology, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-066954

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.